Tue.Jan 03, 2023

article thumbnail

Highlights: What Pharmacists Need to Know about ACIP’s Latest 2023 Vaccination Schedule Updates

Drug Topics

Keep your pharmacy services up to date with the latest 2023 ACIP vaccination schedule updates and recommendations.

Vaccines 200
article thumbnail

Speech Therapy May Effectively Address Long COVID Communication Issues

Pharmacy Times

In addition to the physical symptoms of long COVID, patients have reported vocal, verbal, and cognitive issues that disrupt their ability to communicate.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Teen Drug Overdose Deaths on the Rise

Drug Topics

The CDC has reported an increase in drug overdose deaths from 2019 to 2022 in adolescents aged 10 to 19 years.

201
201
article thumbnail

Opinion: NIH advances landmark recommendations on disability inclusion and anti-ableism

STAT

A diverse and inclusive workforce benefits science and research. But unless it includes people living with a disability — the largest minority group in the U.S. and around the world — research will never be fully representative and science will not reach its full potential. Although 27% of U.S. adults live with a disability, only 10% of science, engineering, and health doctorate holders, and less than 2% of researchers funded by the National Institutes of Health, report having a di

138
138
article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

Improved Access to Direct-acting Antivirals Lowers Hepatitis C Incidence Rates

Pharmacy Times

Study finds a strong decline in hepatitis C incidence in the years immediately following broad access to direct-acting antiviral drugs.

149
149
article thumbnail

CAR-T Therapies Too Costly for Diffuse Large B-Cell Lymphoma Treatment

Drug Topics

Researcher modeling the cost effectiveness of chimeric antigen receptor T-cell therapy (CAR-T) therapy and antibody conjugate found that they fell short.

98

More Trending

article thumbnail

Forks in the road lead one medical expert to a ‘game changing’ liver treatment

PharmaVoice

Durect’s chief medical officer altered his retirement plans to take a leading role at the company, which is developing a treatment for severe alcohol-associated hepatitis.

111
111
article thumbnail

COVID-19 tracker: AstraZeneca workers who were fired for refusing vaccine file lawsuit

Fierce Pharma

COVID-19 tracker: AstraZeneca workers who were fired for refusing vaccine file lawsuit. kdunleavy. Tue, 01/03/2023 - 10:31.

Vaccines 128
article thumbnail

Newron says pivotal treatment-resistant schizophrenia trial is a go

pharmaphorum

Encouraged by new data, Newron Pharmaceuticals has said it will start a registration study of would-be blockbuster evenamide in treatment-resistant schizophrenia (TRS) later this year. The Italian biopharma said it had decided to press ahead with the new study after assessing results from 100 patients with TRS in open-label studies who received the glutamate modulator drug as an add-on to their current therapy for more than six months.

Labelling 105
article thumbnail

Use Cold and Cough Drugs Cautiously in Children

Pharmacy Times

Pharmacists play a vital role in counseling and educating families about medication safety for these products.

128
128
article thumbnail

What the FDA's New Dosage Guidance Means for the Future of Clinical Research

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

article thumbnail

The end-of-life care conundrum

pharmaphorum

Research advises against aggressive cancer treatment at the end-of-life stages of the disease. At the same time, the pharmaceutical industry is creating a greater number of oncology treatments that could provide breakthroughs for patients where none previously existed. Ben Hargreaves examines why there is no easy answer to the question of when palliative care is the right option for patients.

article thumbnail

Covid’s winter surge is poised to exceed summer peak

STAT

The number of people in the United States hospitalized with Covid-19 is about to surpass the figure reached during this summer’s spike, federal data show , as a confluence of factors — from the continued evolution of the coronavirus to holiday gatherings — drives transmission. Notably, the number of people hospitalized with Covid — roughly 40,000 — is still far below the winter waves of 2020-2021 and 2021-2022 (the wave driven by the original Omicron variant) a

Hospitals 100
article thumbnail

Female surgeon creates revolutionary OTC product

Drug Store News

Gail Lebovic’s recent move in health care came in 2020, with the formation of Silicon Valley Innovations, and its OTC flagship product, NasoClenz.

111
111
article thumbnail

STAT+: Medicare would have saved $3.7 billion on Part B drugs if inflationary rebates were around in a recent three-year period

STAT

If rebates had been required for price hikes on most of the nearly 100 medicines covered by Medicare during a recent three-year period, the U.S. government program would have saved $3.7 billion, or 3% of the total spending on so-called Part B medicines, a new analysis found. More specifically, 70 of the 93 top-selling drugs covered by the Medicare Part B program – which are typically pricier medicines that are administered by physicians or in hospitals – between 2018 and 2020 would

article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

11 health benefits of Dry January

The Checkup by Singlecare

After engaging in a fun holiday season with indulgent food and festive drinks, it’s not unusual to long for a reset. For some this takes the form of “Dry January,” a month without drinking any alcohol—or significantly reduced alcohol consumption. “Starting a new year is a good time to make commitments for healthier behaviors,” says Anna Legreid Dopp, Pharm.D. , a senior director at American Society of Health-System Pharmacists (ASHP).

98
article thumbnail

Get care now, pay later?: Health care sees a surge in financing platforms for patients

STAT

As inflation-weary shoppers try to make ends meet, many are turning to a modern twist on the layaway plan: buy now, pay later. But while platforms like Afterpay and Affirm were originally built to take the sting out of online shopping, these new financing options are beginning to creep into the world of health care. “Buy now, pay later is a small fraction of the health space, but it is exploding,” said Jay Zagorksy, an economist at the Questrom School of Business at Boston Universi

98
article thumbnail

What causes diabetes? Diagnosis, prevention, and treatment

The Checkup by Singlecare

What causes diabetes? Diagnosis, prevention, and treatment. Diabetes, also known as diabetes mellitus, is one of the most common health conditions, with around one million Americans diagnosed with diabetes each year. Diabetes can develop in virtually anyone, although, according to the American Diabetes Association (ADA), it is more prevalent in African Americans, Asian Americans, and Hispanics. .

article thumbnail

Opinion: Better information on sexual orientation and gender identity is needed to improve LGBTQ+ health

STAT

Over the past three years, many Americans learned more about epidemiology than they ever knew before. From Covid-19 to mpox to polio, a new generation of citizen scientists is now joining trained professionals in analyzing public health data, forecasting trends, and making personal decisions based on the latest outbreak patterns. But professionals and everyday observers alike are running up against one of the most significant problems in the world of health care data science: the available infor

98
article thumbnail

Counseling Points for Pharmacists on Brain Health Treatments

Pharmacy Times

Indication can play a major role in pharmacists recommending brain health products.

132
132
article thumbnail

STAT+: In wake of House investigation, 5 burning questions for FDA, Biogen, and Alzheimer’s treatments

STAT

A House investigation released last week unearthed a trove of documents that shed new light on the polarizing approval and disastrous rollout of Aduhelm, the first new drug for Alzheimer’s disease in two decades. But crucial questions remain for the Food and Drug Administration, Biogen, and the future of treating Alzheimer’s disease. The FDA has not made clear just what it has changed since the Aduhelm debacle, and the revelations about its inner workings — and the blow to i

FDA 98
article thumbnail

Oregon health agency approves Amazon, One Medical acquisition, moving $3.9B deal one step forward

Fierce Healthcare

Oregon health agency approves Amazon, One Medical acquisition, moving $3.9B deal one step forward. hlandi. Tue, 01/03/2023 - 21:44.

112
112
article thumbnail

Paying research participants — a lot — may be a key to increasing diversity in studies

STAT

Paying people to participate in medical research has been proposed as a way to narrow racial and ethnic gaps in who signs up for clinical trials and other research studies. But a new study finds that if the amount is too small, it could have the opposite effect. Offering $100 to participate in a Covid-19 study enticed affluent and white people while doing little to increase the participation of people from low-income or non-white households.

98
article thumbnail

Scripps Health reaches $3.5M proposed settlement to compensate victims of 2021 ransomware attack

Fierce Healthcare

Scripps Health reaches $3.5M proposed settlement to compensate victims of 2021 ransomware attack. aburky. Tue, 01/03/2023 - 13:13.

111
111
article thumbnail

STAT+: 3 trends to watch in hospitals and health insurance in 2023

STAT

For almost three years, hospitals and health insurers have been riding the waves of the Covid-19 pandemic. Even though they can better predict what lies ahead in 2023, there remain several big unknowns. STAT’s business reporters will be paying attention to three trends in particular: the end of the public health emergency, how hospital price hikes will affect people’s paychecks, and Medicare Advantage’s explosive growth.

article thumbnail

Non-commercial Pharmacies: The Missing Link in Breaking Down Barriers to Medication Access

Pharmacy Times

Patient-centric models of medication delivery that provide cost, transparency, convenience, and accessibility solutions are vital for patients to successfully navigate the current health care system.

article thumbnail

Beijing rebukes new Covid testing requirements for travelers from China

STAT

BEIJING — The Chinese government sharply criticized COVID-19 testing requirements imposed on passengers from China and threatened countermeasures against countries involved, which include the U.S. and several European nations. “We believe that the entry restrictions adopted by some countries targeting China lack scientific basis, and some excessive practices are even more unacceptable,” Foreign Ministry spokesperson Mao Ning said at a daily briefing Tuesday.

96
article thumbnail

Albertsons granted expedited view of temporary restraining order

Drug Store News

Albertsons has been granted a Jan. 17 review of the temporary restraining order against its previously announced $6.85-per-common-share special dividend.

98
article thumbnail

STAT+: The biotech scorecard for the first quarter: 19 stock-moving events to watch

STAT

Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the first quarter: Last year, a novel combination pill developed by Karuna Therapeutics reduced psychosis and related symptoms experienced by patients with schizophrenia, achieving the main goals of a late-stage clinical trial. This quarter, the company hopes to follow up those positive results with the readout of a second, Phase 3 study.

95
article thumbnail

Vanda provides update to Hetlioz ANDA litigation appeal

Drug Store News

The United States Court of Appeals for the Federal Circuit has granted a motion to temporarily enjoin the generic launch by Teva and Apotex of Hetlioz.

98
article thumbnail

Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts

Fierce Pharma

Lilly, Merck double down on peptide-targeted drug delivery, betting billions in biobucks on PeptiDream pacts. ntaylor. Tue, 01/03/2023 - 08:31.

97
article thumbnail

'Podnosis': Digital redlining in healthcare and breaking down barriers to care for gender-diverse populations

Fierce Healthcare

'Podnosis': Digital redlining in healthcare and breaking down barriers to care for gender-diverse populations. tcarey. Tue, 01/03/2023 - 15:06.

98
article thumbnail

Unicycive's pivotal trial of rival to Takeda kidney drug hits main goal, clearing path to FDA filing

Fierce Pharma

Unicycive's pivotal trial of rival to Takeda kidney drug hits main goal, clearing path to FDA filing. ntaylor. Tue, 01/03/2023 - 03:20.

FDA 96
article thumbnail

Physician group practices struggle with bundled payments: study

Fierce Healthcare

Physician group practices struggle with bundled payments: study. fdiamond. Tue, 01/03/2023 - 14:29.

115
115
article thumbnail

Janssen submits marketing application for bispecific antibody

European Pharmaceutical Review

A marketing authorisation application (MAA) has been submitted by The Janssen Pharmaceutical Companies of Johnson & Johnson to the European Medicines Agency (EMA) for approval of talquetamab, a bispecific t-cell engager antibody for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). Talquetamab is an investigational, off-the-shelf treatment targeting both GPRC5D, a novel drug target that is on some normal cells but overexpressed on myeloma cells, and CD3 on t-cell